Chemical Sensitivities Support Forum
Multiple Chemical Sensitivities (MCS)
Multiple Chemical Intollerance
Multiple chemical sensitivity (MCS) is described as a chronic condition characterized by adverse effects from exposure to low levels of chemicals or other substances in modern human environments. Suspected substances include smoke, pesticides, plastics, synthetic fabrics, scented products, petroleum products and paints.
MCS is a controversial diagnosis and is not recognised as an organic illness by the American Medical Association. Blinded trials have shown that MCS patients do not actually react to chemicals, but they do react in unblinded tests when they believe they are being exposed to a trigger. This has led some to believe that MCS symptoms are simply due to odor hypersensitivity  or are mainly psychological.
MCS has also been termed toxic injury (TI), chemical sensitivity (CS), chemical injury syndrome (CI), 20th Century Syndrome, environmental illness (EI), sick building syndrome, idiopathic environmental intolerance (IEI) and toxicant-induced loss of tolerance (TILT).
Six consensus criteria were identified by researchers for the diagnosis and definition of MCS in 1989 (later edited in 1999) :
Symptoms are reproducible with repeated (chemical) exposures.
The condition has persisted for a significant period of time.
Low levels of exposure (lower than previously or commonly tolerated) result in manifestations of the syndrome (i.e. increased sensitivity).
The symptoms improve or resolve completely when the triggering chemicals are removed.
Responses often occur to multiple chemically unrelated substances.
Symptoms involve multiple-organ symptoms (runny nose, itchy eyes, headache, scratchy throat, ear ache, scalp pain, mental confusion or sleepiness, palpitations of the heart, upset stomach, nausea and/or diarrhea, abdominal cramping, aching joints).
The National Institute of Environmental Health Sciences (a division of the NIH) defines MCS as a "chronic, recurring disease caused by a person's inability to tolerate an environmental chemical or class of foreign chemicals". MCS has also been described as a group of "sensitivities to extraordinarily low levels of environmental chemicals" appearing "to develop de novo in some individuals following acute or chronic exposure to a wide variety of environmental agents including various pesticides, solvents, drugs, and air contaminants" including those found in sick buildings.
Environmental Medicine Specialists claim that MCS causes negative health effects in multiple organ systems, and that respiratory distress, seizures, cognitive dysfunction, heart arrhythmia, nausea, headache, and fatigue can result from exposure to levels of common chemicals that are normally deemed as safe.
Ronald E. Gots, M.D., an environmental toxicologist and frequent defense consultant in toxic tort litigation, describes MCS as "a label given to people who do not feel well for a variety of reasons and who share the common belief that chemical sensitivities are to blame. ... It has no consistent characteristics, no uniform cause, no objective or measurable features. It exists because a patient believes it does and a doctor validates that belief." An editorial in the Journal of Toxicology - Clinical Toxicology stated that "It may be the only ailment in existence in which the patient defines both the cause and the manifestations of his own condition."
 Lack of widespread recognition
Because of the lack of scientific evidence based on well-controlled clinical trials that supports a cause-and-effect relationship between exposure to very low levels of chemicals and the myriad symptoms reported by clinical ecologists, MCS is not recognized as an established organic disease by the American Academy of Allergy, Asthma, and Immunology, the American Medical Association (AMA), the California Medical Association, the American College of Physicians, and the International Society of Regulatory Toxicology and Pharmacology. In 1994, the AMA, American Lung Association, US EPA and US Consumer Product Safety Commission published a booklet on indoor air pollution that discusses MCS among other issues. Although sometimes misrepresented as evidence that these entities no longer oppose MCS as a specific disease, the booklet describes MCS as unproven and indicates that other misdiagnosed or undiagnosed diseases cause the symptoms that the patient incorrectly attributes to MCS.
By one count, 25 U.S. administrative agencies afford varying degrees of support to claims filed under MCS. The Social Security Administration states, for example, that "evaluation should be made on an individual case by case basis to determine if the impairment limits substantial gainful activity." This decision is consistent with the SSA's mission to provide support for all workers who are in practice totally disabled, no matter the underlying cause.
The Americans with Disabilities (ADA) Handbook defines environmental illness as "sensitivity to environmental elements" and says that individuals who are severely affected with poor respiratory and neurological function as a result of MCS will satisfy the requirements to be considered disabled. However, lawsuits filed under the ADA's definition have been largely unsuccessful. Some courts have held that MCS "is untested, speculative, and far from generally accepted in the medical or toxicological community," and thus can't be used as the basis for disability claims. Furthermore, accommodations sought for MCS are sometimes denied as being unreasonable as a matter of law.
When MCS sufferers have been tested in double-blinded placebo controlled trials, exposure to chemicals has not reproducibly elicited symptoms. In a 1993 study of MCS sufferers, test subjects could not discriminate between their chemical triggers and clean air when an olfactory masker was introduced that eliminated the ability to discriminate on the basis of odor . In a more recent study (2008), a variety of responses including the subjective perception of being exposed to solvents, increases in blood pressure or heart rate, rash, hypoxia, or increased symptom severity were measured following the double-blinded exposure to several solvents. MCS suffers showed no differences in these parameters whether exposed to clean air or solvents . This evidence refutes the hypothesis that MCS is directly related to the effects of chemical exposures. Since MCS sufferers seem to only have symptoms when they perceive exposure to chemicals, it has been proposed that the syndrome is a result of odor hypersensitivity in which individuals have an exaggerated response to scents.
Symptoms of MCS may be mild to disabling. The symptoms are essentially any symptom which the patient finds distressing and attributes to this cause. A partial list of common symptoms include anaphylactic shock, difficulty breathing, chest pains and asthma, skin irritation, contact dermatitis, and hives or other forms of skin rash, headaches, "brain fog" (short term memory loss, attention deficit), neurological symptoms (nerve pain, paralysis, weakness, trembling, restless leg syndrome, etc.), tendinitis, seizures, visual disturbances (blurring, halo effect, inability to focus), extreme anxiety, panic and/or anger, suppression of immune system, digestive difficulties, nausea, indigestion/heartburn, vomiting, diarrhea, food intolerances, which may or may not be clinically identifiable (e.g., lactose intolerance, celiac disease): commonly wheat and dairy, joint and muscle pains, extreme fatigue, lethargy and lassitude, vertigo/dizziness, abnormally acute sense of smell, sensitivity to natural plant fragrance, natural pine turpines, insomnia, dry mouth, dry eyes, and an overactive bladder.
There is no clear consensus as to what causes the symptoms of MCS. There may be several causes.
More than half of 54 people from one study about MCS instead had somatoform disorder or panic disorder. Other possible explanations include anxiety disorder, lupus, postural orthostatic tachycardia syndrome or other forms of orthostatic intolerance, hay fever and other allergies, hypercalcemia, hypothyroidism, chronic fatigue syndrome, or fibromyalgia. Sufferers may also have a tendency to "catastrophically misinterpret benign physical symptoms" or simply a disturbingly acute sense of smell.
Several mechanisms for psychological etiology have been proposed including theories based on stress, Pavlovian conditioning, or misdiagnoses of an underlying mental illness. Behavior exhibited by MCS sufferers may reflect broader sociological fears about industrial pollution.
The distinction between physiological and psychological causes is often difficult to test and it is particularly challenging for MCS because substances used to test for sensitivity can often be detected by scent. Odor cues make double blind studies of MCS patients difficult, and scents might provoke a psychosomatic response. Research by Dr Mariko Saito et al from the Department of Psychosomatic Medicine at the University of Tokyo in 2005 found that patients only experienced symptoms when they themselves initiated the challenge tests. When they were given random prompts, there was no difference between MCS patients and controls in terms of physical and psychologic symptoms. Their conclusion was "MCS patients do not have either somatic or psychologic symptoms under chemical-free conditions, and symptoms may be provoked only when exposed to chemicals," although their results showed that it was not the chemicals themselves that caused the symptoms.
A review of 37 provocation studies concluded that "persons with MCS do react to chemical challenges; however, these responses occur when they can discern differences between active and sham substances, suggesting that the mechanism of action is not specific to the chemical itself and might be related to expectations and prior beliefs". Critics of such provocation studies assert that they are inconclusive because they often employ masking odors which themselves are alleged to trigger MCS. At least one study attempted to correct for this problem by only using patients who do not respond to the masking odor, and this provocation study similarly showed no correlation between symptoms and chemical exposure.
Another study found strong evidence of a placebo effect: purported MCS sufferers claimed symptoms in nonblinded tests when fed suspected food extracts, but were unable to produce symptoms consistently when the tests were doubleblinded; similarly, patients responded identically to "treatments" and saline.
An alternative psychological cause has been suggested by a recent case-control study in which MCS was an associated with a personality trait called absorption in which individuals are predisposed to becoming deeply immersed in sensory experiences leading to self-altered states of consciousness. When 54 MCS sufferers were compared to 44 subjects with a somatoform disorder and 54 normal individuals, only those with MCS was related to increased absorption scores leading the authors to suggest that absorption contributes to MCS by making individuals more susceptible harboring beliefs in MCS and that these beliefs are reinforced by conditioning 
The cause and existence of MCS are disputed. In particular, doctors disagree about whether symptoms are physiologically or psychologically generated or both. United States courts and several medical organizations reject MCS as a physiological disease. Critics of clinical ecology, a controversial field of medicine that claims to treat MCS, charge that:
MCS has never been clearly defined,
no scientifically plausible mechanism has been proposed for it,
no diagnostic tests have been substantiated, and
not a single case has been scientifically validated.
These claims are challenged, particularly (1) and (2), insofar as both definitions and physiological pathways have actually been proposed. The scientific community remains divided, however, with many proponents of the psychosomatic school rejecting physiological explanations outright.Ronald E. Gots, M.D., an environmental toxicologist and frequent defense consultant in toxic tort litigation, describes MCS as "a label given to people who do not feel well for a variety of reasons and who share the common belief that chemical sensitivities are to blame. ... It has no consistent characteristics, no uniform cause, no objective or measurable features. It exists because a patient believes it does and a doctor validates that belief." An editorial in the Journal of Toxicology - Clinical Toxicology stated that "It may be the only ailment in existence in which the patient defines both the cause and the manifestations of his own condition."
One of the first studies on MCS focused on possible long-term potentiation in the hippocampus and neural sensitization as a central mechanism. Later studies examined the role of the inflammatory process and found that brain inflammation was correlated with symptoms of MCS. In 1999, Meggs proposed that MCS is caused by low molecular weight chemicals that bind to chemoreceptors on sensory nerve C-fibers leading to the release of inflammatory mediators. McKeown-Eyssen showed that polymorphisms in the CYP2D6 allele was responsible for variation in toxicant metabolism pathways that may cause differences in susceptibility to MCS. Pall has suggested elevated nitric oxide and peroxynitrite (NO/ONOO-) as the etiology for MCS and several related conditions including fibromyalgia, post traumatic stress disorder, gulf war syndrome, and chronic fatigue syndrome. This seems to be supported by a study by Reid et al (2001) into the prevalence of MCS amongst British Gulf War Syndrome sufferers. This study concluded that veterans who had used personal organophosphate pesticides during the second Gulf War were 12 times more likely to develop MCS. Many observable and empirical, scientific facts can help identify MCS including SPECT scans and chemical encephalopathy, vitamin deficiencies, mineral deficiencies, excess amino acid deficiency, and disturbed lipid and carbohydrate metabolism.
 Genetically altered detoxification
McKeown-Eyssen studied 203 MCS sufferers and 162 controls and found that blood tests revealed that genetic differences relating to the body's detoxification processes were present more often in those with MCS than those without. Data showed that five genetic polymorphisms have a statistically significant role in determining MCS prevalence. Each of these genes encode proteins that metabolize chemicals previously implicated in MCS, notably the organophosphorus pesticides (PON1 and PON2 genes) and the organic solvents (CYP2D, NAT1 and NAT2 genes). People with a high expression of two specific genes (CYP2D6 and NAT2) were 18 times more likely to have MCS than those without. It was concluded that "a genetic predisposition for MCS may involve altered biotransformation of environmental chemicals." Haley found similar, confirmatory results with the PON1 gene in studies of the Gulf War syndrome veterans. A new study by Schnakenberg et al (2006) confirmed the genetic variation previously found by McKeown-Eyssen and Haley. A total of 521 unrelated individuals participated in the study. Genetic variants of four genes were analyzed: NAT2, GSTM1, GSTT1, and GSTP1. The researchers concluded that individuals who are NAT2 slow acetylators and those with homozygously deleted GSTM1 and GSTT1 genes are significantly more likely to develop chemical sensitivity. According to the study, the glutathione S-transferases act to inactivate chemicals, so people without these GSTM1 and GSTT1 genes are less able to metabolize environmental chemicals because "glutathione S-transferases play an important role in the detoxification of chemicals". The deletion of another gene, the GSTP1 gene, leaves individuals more susceptible to developing these diseases, as lack of these genes means a loss of protection from oxidative stress.
A specific laboratory rat, the Flinders Sensitive Line, has been bred by Dr. Overstreet. It was bred to be sensitive to an organophosphate and displays "Increased sensitivity to cholinergic agents [that] has also been observed in several human populations, including individuals suffering from chemical intolerance." In particular, Flinders Sensitive rats show increased responses to nicotine, alcohol, and other chemicals known to act on acetylcholine, dopamine, and serotonin receptors. However, these rats have not reacted abnormally to other chemicals thought to trigger MCS, such as perfume, in any known studies. Study of these rats may therefore provide useful clues about the mechanisms involved in some, but not all, forms of chemical intolerance in humans.
 Chemical triggers
This article needs additional citations for verification. Please help improve this article by adding reliable references (ideally, using inline citations). Unsourced material may be challenged and removed. (July 2008)
Multiple chemicals are reported to trigger MCS symptoms. In addition to anything which is perfumed or scented, complaints are commonly formed about everyday items:
Tartrazine (a.k.a Yellow #5 or FD&C E102), and other Azo dyes (True allergy must first be excluded)
Caffeine (may cause migraine headaches apart from MCS)
Petrol or gasoline, diesel and exhaust fumes
Petroleum-based products, including petroleum jelly, tar, asphalt
Tobacco or any form of smoke
Pesticides, herbicides, fertilizers, and other agricultural chemicals
Industrial cleaning chemicals, such as dry cleaning fluid
Formaldehyde and aldehyde
Glues, varnishes, polishes, paints, solvents, paint-thinners, and volatile organic compounds (VOC's)
Bleach, fabric softeners, wool-wash, and laundry detergents
Perfumes, lotion, after-shave lotion, nail polish, or skin care products
Air-fresheners, deodorizers and scented candles
Shampoos, hairsprays and hair care products
Household cleaning chemicals
Dishwashing liquid and dishwasher detergent (may cause migraine headaches for those without MCS)
Marking pens, such as highlighters (significant exposure will cause headaches for anyone)
 Miscellaneous theories
Body burden Many heavy metals and chemicals are known to cause illness when excessive amounts are consumed. Smaller amounts of these substances, at levels which are generally recognized as being safe, generally do not cause health problems because the liver and kidneys remove the toxic substances from the body. Some people[who?] theorize that while amounts of individual toxicants that fall within regulatory limits may be safe, the cumulative effect of exposures to multiple toxic substances over a long period of time causes a "body burden", resulting in the symptoms of MCS. While studies have shown that most people have small amounts of many hundreds of toxic chemicals in their body, there is no evidence to show that this correlates to a higher incidence of MCS.
Emotional stresses A recent study at Northwestern University shows that people who have stronger emotional states will react more strongly to a smell. They found that the brain's emotional regions did not better discriminate among the different odors. That discrepancy between brain regions is where anxiety disorders may come in. If someone's olfactory region does not distinguish a dangerous odor signal from a similar one, the brain's emotional fight-or-flight region can overreact.
People who have developed symptoms of MCS have attributed a wide assortment of symptoms to chemical exposure, though symptoms are generally consistent for each individual. The first step in diagnosing a potential MCS sufferer is to identify and treat all other conditions which are present and which often explain the reported symptoms. For example, true allergy, thyroid disorders, orthostatic syndromes, anxiety, and depression need to be carefully evaluated and, if present, properly treated.
The "gold standard" procedure for identifying a person who has MCS is to test his or her response to the random introduction of chemicals that the patient has self-identified as relevant, such as scented soaps or dryer sheets. This may be done in a carefully designed challenge booth to eliminate the possibility of contaminants in the room. Chemicals and controls, sometimes called prompts, are introduced in a random method, usually scent-masked. The test subject does not know when a prompt is being given. Objective and subjective responses are measured. Objective measures often include the galvanic skin response. The galvanic skin response, which is also called electrodermal response, is a reflex that indicates psychological arousal, such as fear, anxiety, or anger. Subjective responses include patient self-reports. A diagnosis of MCS can only be justified when the subject cannot consciously distinguish between chemicals and controls, and when responses are consistently present with exposure to chemicals and consistently absent when prompted by a control.
Researchers in Japan, Spain  and the United States have utilized the Quick Environmental Exposure and Sensitivey Inventory (QEESI) as a self-screening questionnaire for MCS. The QEESI is a shortened version of the Environmental Exposure and Sensitivity Inventory (EESI) developed by Dr. Claudia S. Miller. The QEESI asks individuals to rank their responses to exposures from 0 to 10 in four scales: symptom severity, chemical intolerances, other intolerances, and life impact.
In various studies about one half of the patients who present with symptoms of MCS meet the criteria for depressive and anxiety disorders, and these conditions must be treated when present. The use of SSRI antidepressants with a 53-year-old man with multiple chemical sensitivities showed a dramatic improvement, which suggests, as with the general population, that a subgroup of MCS patients may have an atypical depression and should be evaluated for this condition.
Another study showed psychotherapy resulted in significant, long-term improvement in MCS symptoms, although there was no control group to compare results to.
Saline injections were as successful in alleviating symptoms of food sensitivities as intradermal injection of antigens, suggesting that improvements of food symptoms seen with antigen injection treatment was psychosomatic.
While patients typically resist the potentially stigmatizing diagnosis of an anxiety disorder, many MCS sufferers benefit strongly from lifestyle changes. A 2003 survey of 917 MCS patients revealed that the two most-effective treatments for MCS, in order of self-perceived harm/benefit ratio, were a chemical-free living space and chemical avoidance. Next came prayer and meditation, (which presumably did no harm). By comparison, two-thirds of patients who had tried Zoloft thought it was harmful. Other treatments with perceived harm included other pharmaceutical drugs, provocative neutralization, hydrogen peroxide, Metagenics' UltraClear medical food, and Microhydrin antioxidants. Overall, one or more antidepressants and anxiolytics were rated harmful by about half of survey respondents who had tried them, and as either harmless or helpful by the remaining respondents.
Other treatment modalities variably consists of the avoidance of known irritants, nutritional support to purge the body of its toxic load, sauna detoxification and autolymphycyte factor treatment.
Because many people eliminate whole categories of food in an effort to reduce symptoms, a complete review of the patient's diet may be needed to avoid nutritional deficiencies.
Allergist Theron G. Randolph (1906-1995) was the first to describe "the chemical intolerance phenomenon" in the mid-20th century, calling it "unwitting addiction" and comparing it to drug and alcohol addiction, with the addiction cycle being transparent to the patient as a masked intolerance. When Randolph formulated his views, the term allergy was not connected with immunology, as it has been since the late 1960s. It was then that non-immune-mediated hypersensitivities came to be called "intolerances", "idiopathic" or "idiosyncratic reactions" or "pseudoallergies". Randolph's theory was dismissed from the realm of allergology as the condition is not mediated by the humoral immune system.
As Magill and Seruda report:
Most patients (85 to 90 percent) complaining of MCS syndrome are women. Most present between the ages of 30 and 50 years. Much additional basic descriptive and epidemiologic information is still unknown. The incidence and prevalence are unknown. The question of whether MCS is becoming more or less common is unanswered, as is the question of whether it is preventable. The natural history and biologic outcomes of MCS are unknown, and descriptions of MCS in primary care settings have not been reported. Selected patients from specialty settings comprise reports of the syndrome.
 Cultural references
(1991) In the TV series Northern Exposure, the character Mike Monroe is portrayed as suffering from MCS.
(1995) Safe is a film about a woman who develops MCS.
^ Bob Michaels (1998). "Frequently Asked Questions about Multiple Chemical Sensitivity". http://www.ilru.org/html/publications/readings_in_IL/MCS.html.
Retrieved on 2008-03-20.
^ a b c d e Gots RE (1995). "Multiple chemical sensitivities--public policy". J. Toxicol. Clin. Toxicol. 33 (2): 111–3. PMID 7897748. "The phenomenon of multiple chemical sensitivities is a peculiar manifestation of our technophobic and chemophobic society. It has been rejected as an established organic disease by the American Academy of Allergy and Immunology, the American Medical Association, the California Medical Association, the American College of Physicians, and the International Society of Regulatory Toxicology and Pharmacology. It may be the only ailment in existence in which the patient defines both the cause and the manifestations of his own condition.".
^ a b Bornschein S, Hausteiner C, Römmelt H, Nowak D, Förstl H, Zilker T., Double-blind placebo-controlled provocation study in patients with subjective Multiple Chemical Sensitivity (MCS) and matched control subjects., Clin Toxicol (Phila). 2008 Jun;46(5):443-9.
^ a b c Jewett DL, Fein G, Greenberg MH (August 1990). "A double-blind study of symptom provocation to determine food sensitivity". N. Engl. J. Med. 323 (7): 429–33. PMID 2374564.
^ a b van Thriel C, Kiesswetter E, Schäper M, Juran SA, Blaszkewicz M, Kleinbeck S (2008). "Odor annoyance of environmental chemicals: sensory and cognitive influences". J. Toxicol. Environ. Health Part A 71 (11-12): 776–85. doi:10.1080/15287390801985596. PMID 18569576.
^ Michaels, supra, states: "Some advocates refer to this disability as Chemical Injury Syndrome (CIS), which they believe more effectively communicates the severity of this disability."
^ a b c Joffres MR, Sampalli T, Fox RA (2005). "Physiologic and symptomatic responses to low-level substances in individuals with and without chemical sensitivities: a randomized controlled blinded pilot booth study". Environ Health Perspect 113 (9): 1178–83. doi:10.1289/ehp.7198. PMID 16140624.
^ "Multiple chemical sensitivity: a 1999 consensus". Arch. Environ. Health 54 (3): 147–9. 1999. PMID 10444033.
^ MCSS factsheet — United States National Institute of Environmental Health Sciences
^ Miller CS (1997). "Toxicant-induced Loss of Tolerance-An Emerging Theory of Disease?". Environ Health Perspect. 105 (2): 445–53. doi:10.2307/3433351. PMID 9167978.
^ a b c Gibson, PR, Elms, AN, & Ruding, LA (2003).Perceived treatment efficacy for conventional and alternative therapies reported by persons with multiple chemical sensitivity. Environmental Health Perspectives. 111(12):1498-1504.
^ a b c d Rea, WJ, Johnson, AR, Ross, GH, Butler, JR, Fenyves, EJ, Griffiths, B,& Laseter, J (2006). Considerations for the Diagnosis of Chemical Sensitivity. Retrieved January 1, 2007 from http://www.aehf.com/articles/A55.htm
^ a b An Expert Who Has Been There - Dr. Ronald E. Gots, The Metropolitan Corporate Counsel
^ a b Gots RE. Multiple Chemical sensitivities: What is it? North Bethesda, MD: Risk Communication International, Inc., March 31, 1993.
^ Council on Scientific Affairs, American Medical Association (1992). "Clinical ecology.". JAMA 268 (24): 3465–7. doi:10.1001/jama.268.24.3465. PMID 1460738. ""No evidence based on well-controlled clinical trials is available that supports a cause-and-effect relationship between exposure to very low levels of substances and the myriad symptoms reported by clinical ecologists to result from such exposure . . . . Until such accurate, reproducible, and well-controlled studies are available, the American Medical Association Council on Scientific Affairs believes that multiple chemical sensitivity should not be considered a recognized clinical syndrome."".
^ a b c Magill MK, Suruda A (September 1998). "Multiple chemical sensitivity syndrome". Am Fam Physician 58 (3): 721–8. PMID 9750540. http://www.aafp.org/afp/980901ap/magill.html.
^ Indoor Air Pollution: An Introduction for Health Professionals. Co-sponsored by: The American Lung Association (ALA), The Environmental Protection Agency (EPA), The Consumer Product Safety Commission (CPSC), and The American Medical Association (AMA). 1994. http://www.epa.gov/iedweb00/pubs/hpguide.html#faq1.
Retrieved on 2008-06-30. "[D]efinition of the phenomenon is elusive and its pathogenesis as a distinct entity is not confirmed....The current consensus is that in cases of claimed or suspected MCS, complaints should not be dismissed as psychogenic, and a thorough workup is essential. Primary care givers should determine that the individual does not have an underlying physiological problem and should consider the value of consultation with allergists and other specialists."
^ "Recognition of MCS as a Legitimate Disease and Disability," MCS Referral & Resources fact sheet "(August 1998).
^ Section entitled "Medical Evaluation of Specific Issues: Environmental Illness," SSA Publication 68-0424500, Part 04, Chapter 245, Section 24515.065, Transmittal 12, 1 page excerpt, R-11. On October 31, 1997, Acting SSA Commissioner John Callahan issued a memo to the court officially recognizing MCS "as a medically determinable impairment" on an agency-wide basis. October 31, 1997, R-164, Creamer v. Callahan
^ ADA Handbook, EEOC-BK-19. U.S. Department of Justice and U.S. Equal Employment Opportunities Commission. 111-121:R-17. 1991.
^ Frank v. New York, 972 F. Supp. 130 (N.D.N.Y. 1997)
^ Andrew K. Kelley, "COMMENT: Sensitivity Training: Multiple Chemical Sensitivity and the ADA," 25 B.C. Envtl. Aff. L. Rev. 485; see, for example, Whillock v. Delta Air Lines, 926 F.Supp. 1555 (N.D.Ga. 1995) http://findarticles.com/p/articles/mi_qa3816/is_199801/ai_n8766981/pg_1
^ Staudenmayer H, Selner JC, Buhr MP., Double-blind provocation chamber challenges in 20 patients presenting with "multiple chemical sensitivity". ul Toxicol Pharmacol. 1993 Aug;18(1):44-53.
^ Understanding and Accommodating People With MCS, Pamela Reed Gibson, Ph.D.
^ Bailer J, Witthöft M, Paul C, Bayerl C, Rist F (2005). "Evidence for overlap between idiopathic environmental intolerance and somatoform disorders". Psychosom Med 67 (6): 921–9. doi:10.1097/01.psy.0000174170.66109.b7. PMID 16314597. http://www.psychosomaticmedicine.org/cgi/pmidlookup?view=long&pmid=16314597.
^ Binkley KE, Kutcher S. Panic response to sodium lactate infusion in patients with multiple chemical sensitivity syndrome. J Allergy Clin Immunol 1997;99:570-4.
^ "Idiopathic Environmental Intolerance May Have Psychological Component". http://www.medscape.com/viewarticle/411615.
Retrieved on 2008-01-13.
^ "stoppingSmell". http://www.myhealthsense.com/F010508_stoppingSmell.html.
Retrieved on 2008-01-13.
^ E. Shorter, Multiple chemical sensitivity: pseudodisease in historical perspective, Scand J Work Environ Health 23 (1997) (suppl 3), pp. 35–42
^ a b J. Das-Munshi, G. J. Rubin, S. Wessely, Multiple chemical sensitivities: A systematic review of provocation studies, Journal of Allergy and Clinical Immunology, 118, pp.1257-1264 (2006)
^ Saito M, et al (2005). "Symptom profile of multiple chemical sensitivity in actual life". Psychosomatic Medicine 67 (2 (2005 Mar-Apr)): 318–25. doi:10.1097/01.psy.0000155676.69030.28. PMID 15784800.
^ H. Staudenmayer, J.C. Selner and M.P. Buhr, Double-blind provocation chamber challenges in 20 patients presenting with "multiple chemical sensitivity.", Regul Toxicol Pharmacol 18 (1993), pp. 44–53.
^ Witthöft M, Rist F, Bailer J (2008). "Evidence for a specific link between the personality trait of absorption and idiopathic environmental intolerance". J. Toxicol. Environ. Health Part A 71 (11-12): 795–802. doi:10.1080/15287390801985687. PMID 18569578.
^ Staudenmayer H, Selner JC (June 1995). "Failure to assess psychopathology in patients presenting with chemical sensitivities". J. Occup. Environ. Med. 37 (6): 704–9; discussion 710. doi:10.1097/00043764-199506000-00012. PMID 7670917.
^ S. Barrett, A close look at "Multiple Chemical Sensitivity", 1998
^ Pall, M (2006). Novel disease paradigm produces explanations for a whole group of illnesses. Washington State University, Department of Biochemistry and Basic Medical Sciences, Retrieved December 3, 2006, from: http://molecular.biosciences.wsu.edu/Faculty/pall/pall_main.htm
^ Schnackenberg,E. et al (2007).A cross-sectional study of self-reported chemical-related sensitivity is associated with gene variants of drug-metabolizing enzymes. Environmental Health.
^ a b c Pall ML (September 2003). "Elevated nitric oxide/peroxynitrite theory of multiple chemical sensitivity: central role of N-methyl-D-aspartate receptors in the sensitivity mechanism". Environ. Health Perspect. 111 (12): 1461–4. PMID 12948884.
^ Meggs WJ (1999). "Mechanisms of allergy and chemical sensitivity". Toxicol Ind Health 15 (3-4): 331–8. PMID 10416285.
^ a b c McKeown-Eyssen G, Baines C, Cole DE, Riley N, Tyndale RF, Marshall L, Jazmaji V. (2004). "Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR". Psychosomatic Medicine 33 (5): 971–8. doi:10.1097/01.psy.0000174170.66109.b7. PMID 15256524.
^ Reid, S et al. (2001) Multiple Chemical Sensitivity and Chronic Fatigue Syndrome in Britih Gulf War Veterans. American Journal of Epidemiology Vol.153, No.6, pp604-9.
^ Ziem, G (2001). Medical Evaluation and Treatment of Patients with Chemical Injury and Sensitivity. National Institute of Environmental Health Sciences.
^ Callender TJ, Morrow L, Subramanian K (March 1994). "Evaluation of chronic neurological sequelae after acute pesticide exposure using SPECT brain scans". J Toxicol Environ Health 41 (3): 275–84. PMID 8126750.
^ Heuser G, Mena I, Alamos F (1994). "NeuroSPECT findings in patients exposed to neurotoxic chemicals". Toxicol Ind Health 10 (4-5): 561–71. PMID 7778114.
^ Haley RW, Billecke S, La Du BN (June 1999). "Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans". Toxicol. Appl. Pharmacol. 157 (3): 227–33. doi:10.1006/taap.1999.8703. PMID 10373407.
^ Schnackenberg, E. et al (2007). A cross-sectional study of self-reported chemical-related sensitivity is associated with gene variants of drug-metabolizing enzymes. Environmental Health.
^ "David H. Overstreet & Veljko Djuric, A Genetic Rat Model of Cholinergic Hypersensitivity: Implications for Chemical Intolerance, Chronic Fatigue, and Asthma. Ann. N.Y. Acad. Sci. 933: 92-102 (2001).
^ S. Hojo, H. Kumano, H. Yoshino, K. Kakuta, and S. Ishikawa (2003). "Application of Quick Environment Exposure Sensitivity Inventory (QEESI) for Japanese population: study of reliability and validity of the questionnaire." Toxicology and Industrial Health. 19:41-49
^ S. Nogué, J. Fernández-Solá, E. Rovira, E. Montori, J.M. Fernández-Huerta, and P. Munné (2007). "Multiple chemical sensitivity: study of 52 cases". Medicina Clinica. 129:96-98.
^ C.S. Miller, and T.J. Prihoda, TJ (1999). "A controlled comparison of symptoms and chemical intolerances reported by Gulf War Vetrans, implant recipients and persons with multiple chemical sensitivity." Toxicology and Industrial Health. 15:386-397.
^ C.S. Miller and T.J. Prihoda (1999). "The Environmental Exposure and Sensitivity Inventory (EESI): a standardized approach for measuring chemical intolerances for research and clinical applications." Toxicology and Industrial Health. 15:370-385
^ Lax MB, Henneberger PK (1995). "Patients with multiple chemical sensitivities in an occupational health clinic: presentation and follow-up". Arch. Environ. Health 50 (6): 425–31. PMID 8572720.
^ Andiné P, Rönnbäck L, Järvholm B (July 1997). "Successful use of a selective serotonin reuptake inhibitor in a patient with multiple chemical sensitivities". Acta Psychiatr Scand 96 (1): 82–3. doi:10.1111/j.1600-0447.1997.tb09910.x. PMID 9259230.
^ Lacour M, Zunder T, Dettenkofer M, Schönbeck S, Lüdtke R, Scheidt C (February 2002). "An interdisciplinary therapeutic approach for dealing with patients attributing chronic fatigue and functional memory disorders to environmental poisoning—a pilot study". Int J Hyg Environ Health 204 (5-6): 339–46. doi:10.1078/1438-4639-00103. PMID 11885358.
^ "On Her Last Legs - New York Times". http://www.nytimes.com/2006/02/26/magazine/26wwln_diagnosis.html?_r=1&n=Top/News/Health/Diseases,%20Conditions,%20and%20Health%20Topics/Allergies&pagewanted=print&oref=slogin.
Retrieved on 2008-01-25.
^ a b c Miller, Claudia. Toxicant-induced Loss of Tolerance. Addiction 96 (2000), 115–139.
 See also
Gulf War syndrome
 External links
This article's external links may not follow Wikipedia's content policies or guidelines. Please improve this article by removing excessive or inappropriate external links.
Overview from the MCS support organization Chemical Injury Information Network
Multiple Chemical Sensitivity Resources at The Environmental Illness Resource
MCS Referral & Resources with comparison of MCS to more likely diagnoses
"Clinical Ecological" perspective
Our Toxic Times a monthly magazine by and for those suffering from Multiple Chemical Sensitivities.
Article from Grist Magazine
Mindy Sink, "Seeking Modern Refuge From Modern Life, The New York Times, 19 October 2006, online edition.
Multiple Chemical Sensitivity - The End of Controversy.
Symptom Profile of Multiple Chemical Sensitivity in Actual Life, Saito M, MD et al. 2005
Caryl Schonbrun, "The New Homeless,", MCS International, March 2007.
"Schonbrun advocating for increased public awareness of Multiple Chemical Sensitivity," DRS Connection, Summer 2007 Disabled Resource Services, Fort Collins, Colorado.
Understanding and Accommodating People With MCS, Pamela Reed Gibson, Ph.D., James Madison University]
Martin Pall, Explaining 'Unexplained Illnesses': Disease Paradigm for Chronic Fatigue Syndrome, Multiple Chemical Sensitivity, Fibromyalgia, Post-Traumatic Stress Disorder, Gulf War Syndrome and Others, (Binghampton, New York: Harrington Park Press, 2007), chapter seven, "Multiple Chemical Sensitivity," pp. 111–138.
Multiple Chemical Sensitivity Syndrome A literature review from the American College of Family Phsyicians
", "Townsend Letter for Doctors and Patients, The Examiner of Medical Alternatives: Multiple Chemical Sensitivity...Special Issue, January 2001 - Issue (#210)"
Multiple Chemical Sensitivity: a spurious diagnosis, Stephen Barrett, MD. — A skeptical article hosted on Quackwatch
A close look at "Multiple Chemical Sensitivity", Stephen Barrett, MD, 1998
Comprehensive MCS Bibliography
Findings and Recommendations of The Interagency Workgroup on Multiple Chemical Sensitivity
Retrieved from "http://en.wikipedia.org/wiki/Multiple_chemical_sensitivity"
Forum Link1: Books